The sex hormones dehydroepiandrosterone sulphate (DHEAS), oestradiol, and sex hormone binding globulin (SHBG) were measured in 185 postmenopausal women (aged 45-65 years) with rheumatoid arthritis (RA) and related to assessments ofbone mineral density at the spine and proximal femur. Compared with 518 postmenopausal control women (aged 45-65 years), DHEAS levels were below normal in the 120 patients with RA who had never taken corticosteroids and levels were further depressed in 39 patients currently using steroids. Twenty six patients who had completed steroid treatment also had lower DHEAS levels, suggesting a delayed recovery of adrenal androgen secretion. Oestradiol and SHBG levels were similar in all groups. There was no correlation between sex hormones and disease activity. Oestradiol correlated with bone mineral density at all sites. Although oestradiol correlated with DHEAS, there was no relation between DHEAS and bone mineral density. The cause ofbelow normal levels of DHEAS in RA is unclear, whether a consequence of chronic illness, immune dysfunction, or a defect of adrenal androgen synthesis.
There has been considerable interest in the role of sex hormones in the aetiopathogenesis of rheumatoid arthritis (RA), based on the observed effects of gender, pregnancy, and exogenous oestrogens on the disease. Defective androgen synthesis in men and women has been proposed as a potential predisposing factor for RA', though others suggest low androgen levels to be a secondary phenomenon of chronic disease. 2 screening programme for bone and joint disease and had never received HRT.
In view of the known effects of corticosteroids on bone and sex hormones, patients were analysed by three groups: those who had never taken steroids (never users, 120 women), those who had taken steroids in the past (ex users, 26 women), and those currently maintained on steroids (current users, 39 women). Serum hormone concentrations showed a non-normal distribution and statistical analyses were made using Student's t test following logarithmic transformation of the data. Levels of oestradiol and DHEAS below the sensitivity of the assays were given a value equal to the lowest recordable concentration (20 pmol/l and 0-2 ,umol/l respectively). Variables were compared using Pearson's correlation test. Table 1 lists the disease characteristics of the three RA groups and the controls. The current steroid users, never users, and controls were similar in age, years since the menopause, and weight. There were no significant differences in parameters of disease activity. Compared with tp<0-001.
Results
*p<0-l0.
never users, ex users were significantly lighter (p<0001), had a later menopause (p=003), and had a higher HAQ score (p<0 001).
The serum concentration of DHEAS was significantly lower in all RA groups compared with controls (p<0-001) (table 2) . Lowest values were seen in the current users (p<0.001 v never users), and even ex users had significantly decreased levels compared with never users (p=002). Log SHBG and oestradiol values in the never users and steroid users were similar to controls. The DHEAS level did not correlate significantly with any of the parameters of disease activity (table 3) , but did correlate with oestradiol (r=0-38; p<0-001) and was inversely related to age (r=-0-31; p<Q.01).
Bone mineral density values have been discussed in detail elsewhere'2 and are as follows: lumbar spine controls 0-93 g/cm2, never users 0-92 g/cm2, ex users 0-93 g/cm2, current users 0-85 g/cm2; proximal femur controls 0-87 g/cm2, never users 0-81 g/cm2, ex users 0-79 g/cm2, current users 0-74 g/cm2.
There was no relation between DHEAS and bone mineral density at either measured site. Concentrations of oestradiol were inversely related to years since the menopause (r=-0-45; p<0-001) and age (r=-0-55; p<0 001) as expected, but not weight. There were consistent correlations between oestradiol and bone mineral density at all sites. The SHBG level did not correlate with other hormones or with bone mineral density. The SHBG levels decreased with increased weight (r=-0-4 1; p<0-001), and this relation was also seen in controls.
Discussion
The possible role of androgens as disease mediators in RA has attracted particular interest as subnormal levels have been consistently reported in men with RA,'1'5 though levels in women are less conclusive. Dehydroepiandrosterone sulphate is the most abundant circulating androgen in postmenopausal women and exists as a large circulating pool formed principally by the peripheral sulphation of dehydroepiandrosterone (DHEA), with which it can be interconverted. 6 DHEAS levels in 27 postmenopausal women who were not taking steroids but levels did not correlate with disease duration or functional class. 5 Conversely, a small Italian study of 14 postmenopausal patients with RA found increased levels of DHEAS, testosterone, and androstenedione8 compared with 12 controls and another study found normal androgen levels in 19 postmenopausal patients with RA.7 Interestingly, the latter two studies used patients with osteoarthritis as controls and DHEAS levels were considerably lower in these two control groups than in our own normal population. Furthermore, some patients with osteoarthritis may themselves be hormonally different. 23 Our data are derived from a substantially larger group of patients with RA and controls than previously examined, and confirm that DHEAS levels are subnormal. Whether this observation is a primary or secondary event in RA is unclear. It has been previously shown that chronic diseases may interfere with androgen metabolism.2 3 In contrast with Sambrook et al,5 we were unable to find a correlation between bone density and DHEAS. Sambrook et al reported that DHEAS was a significant predictor of bone density at the femoral neck but not the lumbar spine. A number of population studies have also found weak relations between osteoporosis and DHEAS. Spector et al reported a correlation between DHEAS and spinal but not femoral bone mass'0 and Nordin et al found lower DHEAS levels in women with postmenopausal fractures but no significant correlation between bone mass and DHEAS.9 Another study of postmenopausal women correlated DHEAS with forearm bone mass and vitamin D levels, but the two relations became insignificant after adjustment for age."I Serum oestradiol levels in the RA and control groups were similar, confirming the findings of previous smaller studies. 5 8 25 Levels were often below the detectable range of the assay and results should therefore be interpreted cautiously-nevertheless, oestradiol correlated with bone mineral density at all sites, confirming its importance in the maintenance of the postmenopausal skeleton. There was a significant correlation between oestradiol and DHEAS. Taelman et al showed a relation between DHEA and oestronell and others have shown interconversion of DHEAS with other androgens,'6 21 suggesting that the DHEAS pool may help provide androgen substrate for conversion to oestrogens. This may be an explanation for the previously described relations between DHEAS and bone mass.
Current steroid users showed further decreases of DHEAS levels, likely to be a direct result of reduced ACTH dependent secretion of DHEA, as previously shown.'7 26 27 Oestradiol levels were not suppressed by prednisolone, probably reflecting continued secretion of ovarian androgens.'7 28 The lower values of DHEAS in ex steroid users is surprising, but suggests a delayed recovery of adrenal androgen secretion following cessation of steroid treatment as reported in a patient by Cutler et al.27 In summary, we have found low levels of DHEAS in a large group of postmenopausal women with RA but normal levels of oestradiol and SHBG. As DHEAS values did not correlate with disease activity, we cannot explain these findings on the basis of the effects of chronic illness on androgen metabolism. Dynamic studies would help in our further understanding of the metabolism of androgens in RA, their possible interactive role on pathological mechanisms and their potential therapeutic role in RA.
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